Global Brand Senior Director - GI Cancer

As the Global Brand Director - GI Cancer, you will lead the global commercial strategy for a novel CLDN18.2-targeted antibody-drug conjugate, with the potential to transform outcomes for patients across multiple gastric cancer settings.   Building on a strong launch foundation, you will drive global performance, shape future indications and establish the asset as a benchmark for launch excellence across Oncology. You will lead commercial preparation for the CG-02 indication . The role may also offer a flexible China-based development opportunity, potentially for up to six months, to help accelerate GI Asia priorities, strengthen Global-China collaboration and identify best practices from the asset launch and the wider AstraZeneca enterprise that can be scaled across the organization . The scope, timing and format of any assignment would be subject to further assessment of business priorities, practical feasibility and mutual agreement.   In this role, you will be part of the Global IO Commercial Franchise Team and will set and implement the global brand strategy for this priority ADC asset. The role leads integrated commercial planning across launch, growth and lifecycle development, working with global, regional and country teams and with Marketing, Global Analytics & Insights, Digital, Diagnostics, Pricing and Market Access, Global Medical Affairs, Clinical Development, Regulatory Affairs, Corporate Affairs and other partners.   The role is accountable for creating a differentiated strategy and campaign, generating deep customer and market insights, delivering launch readiness, informing evidence and investment choices, and building market-shaping programs that maximize patient and business impact. It also represents Global Commercial perspectives in relevant cross-functional governance forums.   Typical accountabilities: 1. Global brand strategy and leadership   Set and communicate a clear, differentiated and long-term global brand strategy for the asset aligned with the GI tumor strategy and broader Oncology priorities.   Lead annual strategic and operational planning, including positioning, segmentation, customer strategy, value proposition, target market selection and lifecycle priorities.   Generate deep customer, patient, market and competitive insights and translate them into choices that address unmet need and maximize value.   Develop future-focused revenue forecasts and business cases informed by robust insights and sound commercial judgement.   Represent Global Commercial in relevant Global Product Team and investment decision forums, providing commercially rigorous input to evidence generation and Phase III decisions.   ​ 2. Launch excellence and market shaping   Lead global launch strategy, launch readiness and execution for the asset across priority markets, with clear milestones, decision points and performance measures.   Develop a novel global brand campaign, clear and impactful messaging, core launch tactics and an integrated customer experience approach.   Build distinctive market-shaping programs that increase understanding of the unmet need, CLDN18.2 testing and the evolving role of ADCs in gastric cancer.   Engage regional and country teams early, incorporate market feedback and establish mechanisms to share learning and accelerate adoption of best practice.   Lead agency and vendor relationships, ensuring quality, pace, compliance, value and effective use of resources.   ​ 3. CG-02 indication leadership   Lead commercial preparation for the CG-02 indication as a major future growth opportunity Define the future market, customer needs, competitive differentiation, positioning, value proposition, and launch approach.   Partner with Clinical Development, Medical, Regulatory, Diagnostics and Market Access to ensure commercial insights inform evidence and access strategies.   Build an integrated pre-launch roadmap that enables early market shaping and ensures readiness ahead of anticipated regulatory milestones.   Identify portfolio and enterprise synergies that strengthen the asset's contribution to AstraZeneca’s gastric cancer ambition.   ​ 4. Potential China development opportunity and GI Asia strategic acceleration   The role may include a flexible China-based development assignment, potentially for up to six months. This opportunity remains subject to further investigation and would be shaped around evolving business priorities, the needs of the China and Global teams, practical feasibility and mutual agreement with the successful candidate. If progressed, the assignment would support the GI Asia focus for the asset in line with wider gastric cancer ambitions and enable a two-way flow of insight, capability and best practice between China, Asia and the global organization.   Build first-hand understanding of China’s gastric cancer ecosystem, customer needs, competitive dynamics and routes to patient impact.   Work closely with China Commercial, Medical, Market Access, Diagnostics and cross-functional leaders to support Sone-Ve strategy and execution.   Ensure China and wider Asia insights are systematically incorporated into global strategy, launch planning and lifecycle choices.   Identify , document and actively transfer examples of best practice from asset in China and from wider enterprise work across the organization .   Develop a practical China and Asia best-practice playbook, with recommendations for scaling selected approaches across relevant markets.   Act as a strategic bridge between Global and China teams, strengthening relationships, decision quality and speed of learning.   ​ 5. Business, budget and performance management   Own and manage relevant global brand budgets, forecasts and resource allocation to target, with clear prioritization and financial discipline.   Define a focused performance framework and use leading and lagging measures to identify